Advertisement

Related Videos

The Interventional Pharmacoeconomic Toolbox Panel Discussion

Deborah Collyar: What's In It for Patients?

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Kelvin Chan, MD, FRCPC, MSc, PhD, on Opportunities to Optimize Cancer Drug Policies: The Canadian Perspective

Advertisement

Advertisement




Jan
22
Today In Oncology
Limited or No State Regulation of STLD Health Plans Linked to Decreases in Timely Cancer Treatment Initiation
FDA Releases Draft Guidance for Use of MRD and CR as Primary Endpoints in Multiple Myeloma Trials
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
Regulatory Agencies Establish Principles of Good AI Use in Drug Development
Addition of Durvalumab to BCG After TURBT for BCG-Naive, High-Risk NMIBC
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo